Viking Therapeutics, Inc.'s Phase 2 oral obesity drug data disappointed, showing high discontinuation rates and no clear efficacy or tolerability edge versus competitors. Viking’s lead candidate, ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company ...
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO, Nov. 19, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback